Biotest AG
BIESF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $2 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $2 | $2 | $2 | $2 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 6.1% | 32.6% | 0.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 30.8% | 40.9% | 24.2% | 15.7% |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 16.6% | 26.6% | 4.8% | -3.5% |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 3.6% | 18.6% | -6.1% | -12.3% |
| EPS Diluted | 0.71 | 3.21 | -0.8 | -1.6 |
| % Growth | -77.9% | 501.2% | 50% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | $0 |